How Louisiana’s New Surgeon General Wants To Transform Public Health
Rosemary Westwood, The New York Times / kffhealthnews - Evelyn Griffin is pushing for more emphasis on wellness and prevention. She has also aligned with the MAHA movement in fighting government mandates and questioning the safety of some vaccines.
AI Summary: Louisiana’s new surgeon general outlined an ambitious agenda to revamp public health, prioritizing prevention, health equity and system reforms to tackle chronic disease and access gaps. The plan emphasizes community engagement, measurable targets and pragmatic policy levers—basically, less brochure writing and more fixing the plumbing of a beleaguered health system.
Ex-Fauci adviser pleads guilty to plotting to conceal COVID-19 research records
abcnews - A former senior adviser to infectious disease expert Dr. Anthony Fauci has pleaded guilty to plotting to conceal federal records related to research on the origins of the deadly COVID-19 pandemic
AI Summary: A former scientific adviser to Dr. Fauci pleaded guilty to attempting to conceal COVID‑19 research records, admitting to actions to withhold or obscure documentation related to pandemic studies. The plea resolves part of a wider investigation into recordkeeping and transparency, and underscores legal exposure when internal scientific communications collide with public scrutiny.
FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
oncodaily - The U.S. Food and Drug Administration (FDA) has listed more than 1,500 artificial intelligence-enabled medical devices authorized for marketing in the United States, reflecting the growing integration of AI across […]
AI Summary: The FDA catalogued more than 1,500 AI‑enabled medical devices, spurring criticism that most were cleared without direct evidence they improve patient outcomes. Regulators and clinicians face mounting calls for post‑market studies and transparency, balancing enthusiasm for AI innovation against the sober question: do these devices actually help patients?
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.